news
New tool designed to add or remove sugar from proteins shows success
Researchers have developed a new tool that can add or remove sugar from proteins, which could be used to treat currently "undruggable" targets.
List view / Grid view
Drug Development
news
Mosquito protein could hold key to therapeutics against flaviviruses
A study has shown the mosquito protein AEG12 inhibits flaviviruses, the family of viruses that cause yellow fever, dengue and Zika.
news
New liver-on-a-chip model successfully mimics NAFLD
A liver-on-a-chip model has been developed to more fully represent the natural progression of NAFLD than previous models.
news
Antisense oligonucleotide with potential to combat COVID-19 developed
Scientists have designed a compound named ASO-1 that could help to reduce immune response overactivation in patients with COVID-19.
article
What we know about COVID-19 and the inflammatory response
A year on from discovering COVID-19 we are starting to understand why some people suffer more severely after infection. Sadya Arnett discusses recent research into the interconnection between host inflammation and SARS-CoV-2.
article
Developing bioenergetic nanocatalysts, a novel approach to treat neurodegeneration
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
news
Reversible male contraceptive shows promise in pre-clinical studies
Researchers have discovered the the compound triptonide is safe, effective and reversible as a male contraceptive in animal models.
webinar
Paradigm Shift in Drug Discovery: Discover Small Molecule Degraders Using E3scan™ Technology Platform
4 March 2021 | By Eurofins Discovery
Book your place for our free webinar and learn about how targeted protein degradation (TPD) utilises small molecules to hijack the cellular degradation machinery through the recruitment of E3 ubiquitin ligases to proteins of interest.
webinar
The discovery and challenges of antibodies targeting GPCRs
26 February 2021 | By Domain Therapeutics
Watch our on-demand webinar which focused on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.
news
Behavioural screen in C. elegans reveals Parkinson’s drug candidates
Researchers have developed a workflow to study the behaviour of C. elegans in a high-throughput screen to identify Parkinson's disease drugs.
news
Over 87,000 papers published on coronavirus since start of pandemic
Between January and October 2020, scientists globally have published more than 87,000 papers about the coronavirus.
news
Team modifies therapeutic molecule to improve stroke treatment
Researchers have shown that adding a polymer to glutamate-oxaloacetate transaminase means the molecule can treat stroke for up to six days in rats.
news
New drug combination could combat Diffuse Intrinsic Pontine Glioma
The drug combination of difluoromethylornithine and AMXT 1501 has shown success against Diffuse Intrinsic Pontine Glioma in animal models.
article
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
article
SARS-CoV-2 and immunology: antibody developments
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
